No Data
No Data
Potential Catalysts and Strategic Focus: Analyzing Alto Neuroscience's Upcoming Trials and Precision Psychiatry Approach
Alto Neuroscience Strengthens Financial Position Amid Increased R&D
Alto Neuroscience Analyst Ratings
Stifel Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $10
Express News | Alto Neuroscience Inc : Stifel Cuts Target Price to $10 From $32
TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
No Data
No Data